搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

Your Good Partner in Biology Research

  1. 首頁
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human Carbonyl reductase [NADPH] 1 (CBR1/CBR/CRN) ELISA kit

Human Carbonyl reductase [NADPH] 1 (CBR1/CBR/CRN) ELISA kit

  • 中文名稱：
    人羰基還原酶[NADPH] 1 (CBR1/CBR/CRN)酶聯(lián)免疫試劑盒
  • 貨號：
    CSB-E17009h
  • 規(guī)格：
    96T/48T
  • 價格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    人羰基還原酶[NADPH] 1 (CBR1/CBR/CRN)酶聯(lián)免疫試劑盒（CSB-E17009h）為雙抗夾心法ELISA試劑盒，定量檢測血清、血漿、組織勻漿樣本中的CBR1含量。CBR1即大麻素受體 1，廣泛分布于中樞神經(jīng)系統(tǒng)等部位。它與內(nèi)源性大麻素系統(tǒng)密切相關(guān)，參與調(diào)控食欲、記憶、情緒等生理過程。研究機制方面，聚焦其信號通路、與配體相互作用等，探索通過調(diào)節(jié)CBR1治療相關(guān)疾病的可能。試劑盒檢測范圍為31.25 pg/mL-2000 pg/mL，適用于科研領(lǐng)域中對CBR1表達調(diào)控的探索，如藥物代謝動力學(xué)研究、腫瘤耐藥機制分析、氧化應(yīng)激相關(guān)疾病模型構(gòu)建等基礎(chǔ)研究場景。本品僅用于科研，不用于臨床診斷，產(chǎn)品具體參數(shù)及操作步驟詳見產(chǎn)品說明書。
  • 別名：
    15 hydroxyprostaglandin dehydrogenase [NADP+] ELISA Kit; 15-hydroxyprostaglandin dehydrogenase [NADP+] ELISA Kit; Carbonyl reductase [NADPH] 1 ELISA Kit; Carbonyl Reductase 1 ELISA Kit; CBR 1 ELISA Kit; CBR1 ELISA Kit; CBR1_HUMAN ELISA Kit; CRN ELISA Kit; NADPH dependent carbonyl reductase 1 ELISA Kit; NADPH-dependent carbonyl reductase 1 ELISA Kit; Prostaglandin 9 ketoreductase ELISA Kit; Prostaglandin 9-ketoreductase ELISA Kit; Prostaglandin E(2) 9 reductase ELISA Kit; Prostaglandin-E(2) 9-reductase ELISA Kit; SDR21C1 ELISA Kit
  • 縮寫：
    CBR1
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum, plasma, tissue homogenates
  • 檢測范圍：
    31.25 pg/mL-2000 pg/mL
  • 靈敏度：
    7.81 pg/mL
  • 反應(yīng)時間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測波長：
    450 nm
  • 研究領(lǐng)域：
    Cell Biology
  • 測定原理：
    quantitative
  • 測定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%
    Three samples of known concentration were tested twenty times on one plate to assess.
    Inter-assay Precision (Precision between assays): CV%<10%
    Three samples of known concentration were tested in twenty assays to assess.
  • 線性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human CBR1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    　 Sample Serum(n=4)
    1:1 Average % 90
    Range % 85-97
    1:2 Average % 85
    Range % 80-89
    1:4 Average % 94
    Range % 90-98
    1:8 Average % 102
    Range % 98-107
  • 回收率：
    The recovery of human CBR1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample Type Average % Recovery Range
    Serum (n=5) 96 92-100
    EDTA plasma (n=4) 89 84-93
  • 標準曲線：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    pg/ml OD1 OD2 Average Corrected
    2000 2.319 2.214 2.267 2.142
    1000 1.394 1.452 1.423 1.298
    500 0.825 0.870 0.848 0.723
    250 0.471 0.487 0.479 0.354
    125 0.308 0.295 0.302 0.177
    62.5 0.247 0.239 0.243 0.118
    31.25 0.153 0.161 0.157 0.032
    0 0.122 0.128 0.125 　
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評價

相關(guān)問答

■ 常見問題解答
Q:

is it possible to use Cat#E17009H Human Carbonyl reductase [NADPH] 1 (CBR1/CBR/CRN) ELISA kit 96 tests for mouse samples too, is it possible to test this maybe?

A:
Thanks for your inquiry!
It is not recommended to use the kit CSB-E17009H to detect mouse samples.
Because the protein of mouse and human Carbonyl reductase CBR1 are different. Also the antibody specificity of 2 kits is different.
There exsits sample matrix difference between mouse and samples.
We advise you not use the kit of across species.

靶點詳情

  • 功能：
    NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E to prostaglandin F2-alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione.
  • 基因功能參考文獻：
    1. This study examined the impact of the functional single nucleotide polymorphism CBR1 rs9024 on the bioactivation of loxoprofen in a collection of human liver samples and tumor cell lines. PMID: 29851133
    2. CRB1 is an efficient catalyst for the reduction of glutathionylated aldehydes derived from lipid peroxidation. PMID: 27562619
    3. The ability of human carbonyl reductase 1 to efficiently catalyze the reduction of glutathionylated aldehydes derived from lipid peroxidation, that in the case of glutathionylated-4-hydroxyalkanals is associated to the ability to oxidize the hemiacetal hydroxyl group PMID: 28274719
    4. Data suggest that fatty acids and acyl-CoAs bind competitively with respect to substrate binding to carbonyl reductase 1 (CBR1), an enzyme involved in first-pass drug metabolism in intestinal mucosa; inhibition of CBR1 by these products of digestion may lead to food-drug interactions. PMID: 28450226
    5. AKR1C3 is the primary enzyme and CBR1 is a minor enzyme responsible for warfarin reduction in human liver cytosol. PMID: 27055738
    6. These results suggest that CR1 induces apoptosis by activating the caspase pathway via binding to TNFR1. PMID: 26499922
    7. Results demonstrate a trend toward decreased functional expression of selective hepatic reductases in ESRD livers. PMID: 26282591
    8. Critical insights into the substrate selectivity of hCBR1 and the interaction between hCBR1 and glutathione. PMID: 26381805
    9. Up-Regulation of Carbonyl Reductase 1 Renders Development of Doxorubicin Resistance in Human Gastrointestinal Cancers PMID: 26328486
    10. CBR1 decreases promoted tumor proliferation and growth as well as invasion and metastasis; CBR1 has potential to become a new candidate for molecular targeting therapy. PMID: 25572536
    11. Inhibition of CBR1 may increase the efficacy of daunorubicin in cancer tissue. PMID: 25541467
    12. Protein products of AKR1C1, AKR1C2, AKR7A3, CYP3A4, and carbonyl reductase (CBR1) were found in tumors and those of AKR1C1, AKR7A3, and CBR1 correlated with their transcript levels. PMID: 25526449
    13. we suggest that PEP-1-CBR1 protein may be a therapeutic agent for the treatment of ischemic injuries as well as oxidative-stress-induced cell damage and death. PMID: 24440593
    14. The stimulatory effect of cortisol on CBR1 expression may partly explain the concurrent increases of cortisol and prostaglandin PGF2alpha in human amnion tissue prior to the onset of labor PMID: 24654784
    15. Nrf2 is a novel transcriptional regulator of CBR1 genes in humans. PMID: 23247010
    16. GSNO-induced covalent modification of cysteine residues affects the kinetic mechanism of CBR1. PMID: 23295225
    17. regulation of human CBR1 expression by hsa-miR-574-5p and hsa-miR-921 depends upon rs9024 genotype status PMID: 23133646
    18. This pilot study suggests that CBR1 RNA expression may be helpful in identifying AML patients at risk of developing resistance or toxicity to daunorubicin due to increased formation of daunorubicinol. PMID: 22562609
    19. CBR1 regulates cancer cell invasion in endometrial adenocarcinomas by regulating the epithelial mesenchymal transition PMID: 22542806
    20. Polymorphisms in CBR1 gene did not increase risk of cardiomyopathy after anthracycline treatment of childhood cancers. PMID: 22124095
    21. a physiological role of CBR1, but not for CBR3, in S-nitrosoglutathione reduction and thus ultimately in regulation of NO signaling PMID: 21256830
    22. This protein has been found differentially expressed in thalami from patients with schizophrenia. PMID: 20471030
    23. analysis of the structural basis for substrate specificity in human monomeric carbonyl reductases CBR1 PMID: 19841672
    24. the functional genetic determinant of CBR1 activity toward relevant physiological and pharmacological substrates PMID: 17344335
    25. The functional characterization of the promoter of CBR1 is reported. PMID: 17569794
    26. Carbonyl reductase-1 (CBR1), microsomal prostaglandin E synthase-1 and 2 (mPGES-1, mPGES-2), cytosolic prostaglandin E synthase (cPGES), aldoketoreductase (AKR1C1) and prostaglandin F synthase (AKR1C3) were all expressed in hair follicles. PMID: 17697149
    27. These results suggested that hCBR3 and hCBR1 play distinct physiological roles. PMID: 18493841
    28. Human carbonyl reductase 1 is an S-nitrosoglutathione reductase PMID: 18826943
    29. CBR1 polymorphisms have a significant influence on the pharmacokinetics of doxorubicin in Asian breast cancer patients. PMID: 19016765
    30. the nonsynonymous single nucleotide polymorphisms generating mutations OF CBR1 may alter bioavailability of anthracyclines in cancer patients PMID: 19204081

    顯示更多

    收起更多

  • 亞細胞定位：
    Cytoplasm.
  • 蛋白家族：
    Short-chain dehydrogenases/reductases (SDR) family
  • 組織特異性：
    Expressed in kidney (at protein level).
  • 數(shù)據(jù)庫鏈接：

    HGNC: 1548

    OMIM: 114830

    KEGG: hsa:873

    STRING: 9606.ENSP00000290349

    UniGene: Hs.88778